BullFrog AI jumps after positive preclinical study of drug treating glioblastoma

Bullfrog AI Holdings

26/09/2023 14:23

** Shares of digital biopharmaceutical company BullFrog AI
Holdings  BFRG.O  rise 18.1% to $3.37 premarket
    ** Co announces positive data in a preclinical study
investigating the anti-cancer activity of a novel prodrug of
mebendazole for the treatment of glioblastoma
    ** Glioblastoma is a fast-growing and aggressive type of
cancer that occurs in the brain or spinal cord
    ** "This is the first study to demonstrate that BF-223, a
novel mebendazole prodrug, has anti-cancer activity in animals,"
said Vin Singh, Chairman and CEO of BullFrog AI
    ** Up to last close, stock down ~46% since its debut in
February

 (Reporting by Jaiveer Singh Shekhawat in Bengaluru)
 ((JaiveerSingh.Shekhawat@thomsonreuters.com;))